Antibody Therapeutics Stocks
Biotechnology firms in this sector specialize in the engineering of monoclonal antibodies, bispecifics, and antibody-drug conjugates to modulate immune responses or target specific cellular receptors.
As of Oct 23, 2026, Antibody Therapeutics has 69 US-listed companies worth $143B combined. The median member moved +2.3% over the past week; TRAX led among the 25 largest at +27.8% and AVTX trailed at -38.5%.
Companies in Antibody Therapeutics
- ARGX – argenx NV ADR, $54.9B
- GMAB – Genmab AS, $26.9B
- SYRE – Spyre Therapeutics Inc., $8.7B
- IMVT – Immunovant Inc, $5.9B
- KOD – Kodiak Sciences Inc, $5.4B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- ABCL – Abcellera Biologics Inc, $3.8B
- VRDN – Viridian Therapeutics Inc, $2.5B
- CLDX – Celldex Therapeutics Inc, $2.3B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- XNCR – Xencor Inc, $1.9B
- VIR – Vir Biotechnology Inc, $1.8B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- KRSA – Korsana Biosciences, Inc., $1.5B
- TRAX – First Tracks Biotherapeutics, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- JANX – Janux Therapeutics Inc, $1.1B
- AVTX – Avalo Therapeutics Inc, $728M
- OABI – OmniAb Inc., $663M
- CLYM – Climb Bio Inc, $592M
- CTMX – CytomX Therapeutics Inc, $556M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- CBIO – Crescent Biopharma, Inc., $532M
- ACRS – Aclaris Therapeutics Inc, $483M
- TECX – Tectonic Therapeutic, Inc., $444M
- PRTA – Prothena Corporation plc, $435M
- AGMB – AgomAb Therapeutics NV American Depositary Shares, $422M
- ZURA – Zura Bio Limited Class A Ordinary Shares, $396M
- SRZN – Surrozen Inc, $276M
- AGEN – Agenus Inc, $273M
- SABS – SAB Biotherapeutics Inc, $262M
- QTTB – Q32 Bio Inc, $232M
- MGNX – MacroGenics Inc, $218M
- ADCT – ADC Therapeutics SA, $217M
- ALEC – Alector Inc, $214M
- WHWK – Whitehawk Therapeutics, Inc., $194M
- ELDN – Eledon Pharmaceuticals Inc, $190M
- YARW – Yarrow Bioscience Inc, $183M
- IVVD – Invivyd Inc., $182M
- STRO – Sutro Biopharma, $181M
- ADAG – Adagene Inc, $165M
- IPHA – Innate Pharma, $160M
- NBP – NovaBridge Biosciences, $158M
- CHRS – Coherus BioSciences Inc, $156M
- VRXA – Veraxa Biotech AG Ordinary Shares, $156M
- UPB – Upstream Bio, Inc., $151M
- CMPX – Compass Therapeutics Inc., $150M
- OSTX – OS Therapies Incorporated, $75.8M
- PMN – ProMIS Neurosciences Inc., $74.3M
- IBIO – iBio, Inc. Common Stock, $72.3M
- APLM – Apollomics Inc. Class A Ordinary Shares, $67.8M
- XBIT – XBiotech Inc, $65.9M
- HYFT – ImmunoPrecise Antibodies Ltd., $60.8M
- XLO – Xilio Development Inc, $58.6M
- IMA – ImageneBio, Inc., $52.4M
- CNTX – Context Therapeutics Inc, $28.9M
- NXTC – NextCure Inc, $24.9M
- JSPR – Jasper Therapeutics Inc, $19M
- RADX – Radiopharm Theranostics Limited American Depositary Shares, $15.8M
- GTBP – GT Biopharma Inc, $14.5M
- IMRN – Immuron Ltd ADR, $9.4M
- BOLT – Bolt Biotherapeutics, $7.7M
- APVO – Aptevo Therapeutics Inc, $3.1M
- BCAB – Bioatla Inc, $2.5M
- PPBT – Purple Biotech, $2.5M
- KAPA – Kairos Pharma, Ltd., $2M
- SCNI – Scinai Immunotherapeutics Ltd, $826,686
- SRNE – Sorrento Therape, $441,024